Consortium lead by Prophylix Pharma AS receives up to €6 M in…
The EU grant is for development of a prophylactic treatment to prevent severe bleeding and death in newborns caused by Fetal/Neonatal Alloimmune Trombocytopenia
(PRWeb May 08, 2012)
Read the full story at http://www.prweb.com/releases/2012/5/prweb9483311.htmClick here for reuse options!
Copyright 2012 Biotechblog
Comments are closed.